vs
DYNEX CAPITAL INC（DX）与Viridian Therapeutics, Inc.\DE（VRDN）财务数据对比。点击上方公司名可切换其他公司
Viridian Therapeutics, Inc.\DE的季度营收约是DYNEX CAPITAL INC的1.6倍（$70.6M vs $43.5M），Viridian Therapeutics, Inc.\DE同比增速更快（81958.1% vs 531.3%）
Dynex Capital Inc是一家总部位于美国的上市房地产投资信托公司，专注于投资和管理抵押贷款支持证券、住宅及商业抵押贷款等各类抵押相关资产组合，通过稳健运营为股东创造稳定分红和长期资本增值。
Viridian Therapeutics是一家临床阶段生物技术企业，专注于为罕见重症自身免疫及炎症性疾病患者开发新型疾病修饰疗法，核心管线候选产品针对甲状腺眼病，主要业务及市场覆盖北美与欧洲地区。
DX vs VRDN — 直观对比
营收规模更大
VRDN
是对方的1.6倍
$43.5M
营收增速更快
VRDN
高出81426.8%
531.3%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.5M | $70.6M |
| 净利润 | — | $-34.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -56.7% |
| 净利率 | — | -49.0% |
| 营收同比 | 531.3% | 81958.1% |
| 净利润同比 | — | 54.9% |
| 每股收益（稀释后） | $1.59 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXVRDN
| Q4 25 | $43.5M | — | ||
| Q3 25 | $30.6M | $70.6M | ||
| Q2 25 | $23.1M | — | ||
| Q1 25 | $17.1M | — | ||
| Q1 24 | $-3.2M | — | ||
| Q4 22 | $6.2M | — | ||
| Q3 22 | $7.1M | — | ||
| Q2 22 | $14.1M | — |
净利润DXVRDN
| Q4 25 | — | — | ||
| Q3 25 | $150.4M | $-34.6M | ||
| Q2 25 | $-13.6M | — | ||
| Q1 25 | $-3.1M | — | ||
| Q1 24 | $40.1M | — | ||
| Q4 22 | $43.3M | — | ||
| Q3 22 | $-46.7M | — | ||
| Q2 22 | $29.3M | — |
营业利润率DXVRDN
| Q4 25 | — | — | ||
| Q3 25 | — | -56.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
净利率DXVRDN
| Q4 25 | — | — | ||
| Q3 25 | 491.3% | -49.0% | ||
| Q2 25 | -58.8% | — | ||
| Q1 25 | -18.0% | — | ||
| Q1 24 | -1256.8% | — | ||
| Q4 22 | 697.2% | — | ||
| Q3 22 | -655.3% | — | ||
| Q2 22 | 208.5% | — |
每股收益（稀释后）DXVRDN
| Q4 25 | $1.59 | — | ||
| Q3 25 | $1.08 | — | ||
| Q2 25 | $-0.14 | — | ||
| Q1 25 | $-0.06 | — | ||
| Q1 24 | $0.64 | — | ||
| Q4 22 | $0.44 | — | ||
| Q3 22 | $-1.07 | — | ||
| Q2 22 | $0.69 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $531.0M | $490.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.5B | $503.0M |
| 总资产 | $17.3B | $577.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DXVRDN
| Q4 25 | $531.0M | — | ||
| Q3 25 | $491.0M | $490.9M | ||
| Q2 25 | $387.5M | — | ||
| Q1 25 | $327.4M | — | ||
| Q1 24 | $295.7M | — | ||
| Q4 22 | $332.0M | — | ||
| Q3 22 | $260.4M | — | ||
| Q2 22 | $325.7M | — |
股东权益DXVRDN
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.0B | $503.0M | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.4B | — | ||
| Q1 24 | $958.5M | — | ||
| Q4 22 | $901.3M | — | ||
| Q3 22 | $771.3M | — | ||
| Q2 22 | $842.4M | — |
总资产DXVRDN
| Q4 25 | $17.3B | — | ||
| Q3 25 | $14.2B | $577.1M | ||
| Q2 25 | $11.3B | — | ||
| Q1 25 | $9.0B | — | ||
| Q1 24 | $6.3B | — | ||
| Q4 22 | $3.6B | — | ||
| Q3 22 | $4.0B | — | ||
| Q2 22 | $3.2B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $120.8M | $-84.6M |
| 自由现金流经营现金流 - 资本支出 | — | $-84.7M |
| 自由现金流率自由现金流/营收 | — | -120.1% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DXVRDN
| Q4 25 | $120.8M | — | ||
| Q3 25 | $68.3M | $-84.6M | ||
| Q2 25 | $31.9M | — | ||
| Q1 25 | $6.4M | — | ||
| Q1 24 | $-17.1M | — | ||
| Q4 22 | $30.1M | — | ||
| Q3 22 | $25.5M | — | ||
| Q2 22 | $36.2M | — |
自由现金流DXVRDN
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
自由现金流率DXVRDN
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
资本支出强度DXVRDN
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
现金转化率DXVRDN
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | -0.43× | — | ||
| Q4 22 | 0.69× | — | ||
| Q3 22 | — | — | ||
| Q2 22 | 1.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
